The seven strangest historical discoveries made in 2025
When you buy through links on our articles, Future and its syndication partners may earn a commission.
No matter how many books and TV documentaries are made appearing to give a definite account of life in ancient civilizations, the ongoing work of historians and archaeologists means that the story of the past is never finished. There are always new discoveries being made – here are seven of the most surprising.
A form of ancient sunscreen could have helped Homo sapiens survive a period of intense environmental stress that killed off the Neanderthals, scientists have suggested.
The two species existed alongside each other for millennia until about 40,000 years ago, when Neanderthals disappeared. The reason for their demise is not entirely clear, but one factor may have been the shift of the Earth's magnetic poles that occurred around that time. Known as Laschamps excursion, this phenomenon lasted 1,000 years and weakened Earth's magnetic field to about 10% of its current strength, leading to a massive increase in solar radiation.
Researchers in Michigan have found evidence that Homo sapiens developed what may have been protective strategies: they took shelter in caves and ramped up their extraction of the pigment ochre, perhaps because they were using it to paint their bodies. Needles and awls unearthed at Stone Age sites also indicate the use of tailored clothes – which would have kept them warmer too, enabling them to travel further for food. But there is little evidence that the Neanderthals adapted in such ways. Solar radiation can damage sight and lead to birth defects and infant deaths – so protection from it would "have conferred significant advantage", said Raven Garvey, who co-authored the study.
The eruption of Vesuvius almost 2,000 years ago buried Herculaneum and Pompeii under a thick layer of ash, which preserved everything from its residents to the frescoes in their villas. Numerous bodies have been excavated, but one is more unusual than most: that of a young man who was found lying in his bed – and whose brain appeared to have been turned to glass. When this was observed in 2020, such a phenomenon had never been seen before, and scientists were baffled as to how it could have occurred. Now a team have come up with a possible explanation.
For glass to have formed, the tissue would have had to have heated very rapidly until it liquefied, then cooled fast enough to prevent crystals forming as it solidified. Analysis of fragments of the man's brain has shown that it was heated to 510C, before fast-cooling. The pyroclastic flows from the volcano did not get that hot; nor would they have allowed for rapid cooling. However, the ash cloud that swept through the town first would have been far hotter. This heat, says the study, could have evaporated the water in the man's brain, causing it to explode into tiny pieces. The cloud would then have rapidly cleared, allowing the fragments to cool and vitrify.
We think of gladiators being made to fight tigers, lions or bears as a staple of the Roman circus. But though the Romans wrote about such spectacles and depicted them in frescos and mosaics, there has never been any direct physical evidence for their existence – until now. Archaeologists have analysed wounds on the hip bone of a gladiator who died in England in the 3rd century AD, and concluded that their shape is "consistent" with the bite marks of large cats, with lions being the closest fit.
The skeleton was one of dozens unearthed 20 years ago in a cemetery in York. Most belonged to well-built young men, and had been decapitated; their bones bore marks of injuries inflicted by blades; one had been shackled; and DNA tests indicated that they came from all over the Roman empire. All of which led the team to conclude that they were gladiators. The researchers do not think that this gladiator was killed by the lion bite, however, but that he'd been injured already and was dragged off at the point of death – which "must have been absolutely terrifying", said Tim Thompson, one of the study's authors. Given the difficulty of transporting big cats, the find also underlines the importance of York in the Roman world.
Archaeologists have been startled to find evidence that humans lived on Malta some 8,500 years ago. The findings, published in Nature, mean that the seafaring abilities of hunter-gatherers must be rethought. Previously, it was assumed that journeys of such length across the Mediterranean only started following the invention of boats with sails.
The archaeologists, from the Max Planck Institute of Geoanthropology, believe that they arrived in dug-out canoes, having undertaken a journey in open water of at least 100km, some of which (given the limited speed of such vessels) must have been in darkness.
The island is so small and isolated, the presumption had been that it could not have sustained a population that wasn't growing its own food. But carbon dating of charcoal, found in hearths outside a cave complex in the north of the island, indicates that hunter-gatherers were there a millennium before farming became widespread. Other evidence at the site shows that these ancient people hunted meat, in the form of deer, birds and seals; they also cooked sea urchins, crab and fish.
The Romans came into so much contact with lead – via everything from their paints to their coins, water pipes and drinking vessels – that historians have long speculated that lead poisoning could have hastened the fall of their empire. Now, a study has shown that there were also high levels of lead in the air they breathed – enough, in fact, to have affected brain development.
Romans' mining of lead and their smelting of lead ore to obtain silver would have released vast amounts of lead into the atmosphere. To gauge the scale of this, a team in the US analysed residues trapped in ice that formed between 500BC and AD600. Their findings indicate that levels of the neurotoxin in the air increased sharply in around 15BC, and remained high for two centuries. They then used atmospheric models to map the pollutants' spread, and modern health studies to assess its impact.
Their results showed that, at its peak, the lead pollution across Europe (believed to be the first widespread industrial pollution) was severe enough to cause a two-to three-point drop in IQ. That might not sound much, but, "when you apply [it] to essentially the entire European population, it's kind of a big deal", said co-author Nathan Chellman.
In our "always on" world, there is a feeling that no one is getting enough sleep; and that the time we spend staring at screens is preventing us from sleeping well. Yet according to recent research, we get more – and better – sleep than our ancestors in pre-industrial times are likely to have done.
For a study published in the Proceedings of the Royal Society B, scientists in Canada analysed data on the sleep patterns of 866 people in 54 sleep studies from around the world – from the residents of big cities to the members of hunter-gatherer tribes. They found that the participants living in industrial societies slept more, clocking up an average of 7.1 hours a night compared with just 6.4 in the less industrial societies.
And they also found there had been no significant decline in sleep in Westernised places over the past half-century. The study also revealed that people in these societies tend to get more efficient sleep – meaning they are asleep for more of the time they spend in bed (88% compared with 74%). The researchers suggest modern living conditions are simply more conducive to restful sleep: "We don't have to fend with rival human groups at night or predators," said David Samson.
But if that is the case, why then do so many people in the West seem to wake up feeling exhausted? This may be due to the study's other main finding, which is that people living in industrialised countries have a less regular circadian rhythm: their sleep patterns don't match the natural cycles of light and dark.
When the Romans invaded Britain, they found the natives strange, says The Times. Their warriors painted themselves blue; and they had moustaches – a concept so foreign to Romans, they had no name for it. Perhaps worst of all, Roman scribes recorded that Celtic rebellions against Roman rule were often led by women. This would have seemed outlandish in Rome, where women were legally owned by their fathers and their husbands, and had no role at all in public life.
But while the existence of female warriors such as Boudicca is not in doubt, historians have long distrusted these accounts, suspecting the extent of female power and influence was overstated, to make Celtic societies seem completely barbaric. Now, however, archaeologists at Trinity College Dublin and Bournemouth University have backed up the scribes' observations.
The research was based on the remains of 57 people unearthed at an Iron Age cemetery in Dorset. By tracing mitochondrial DNA (which is only passed on by women), the team established that most of the female members of this community were related and all descended from a single woman; by contrast, there was considerable diversity in the male Y chromosomes, suggesting that the men came from lots of different families.
This, the study says, indicates that men moved into their wives' community on marriage – a pattern known as matrilocality – perhaps because land and wealth passed down through the female line. The grave goods found back up this theory: the higher status items tended to have been buried with women.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
By Deena Beasley (Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen. The full Phase 3 results were presented in Chicago at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. In the obesity trial, 79.6% of CagriSema patients had mainly transient, mild-to-moderate gastrointestinal effects such as nausea, vomiting and constipation, compared with 39.9% of placebo patients. Serious adverse events occurred in 9.8% of CagriSema patients and 6.1% of placebo patients. In the CagriSema group, 6% of patients dropped out of the trial due to adverse events, compared with 3.7% in the placebo group. "Everything was in line with what we expected," Dr. Melanie Davies, lead investigator of the CagriSema diabetes trial, and co-director of the Leicester Diabetes Centre, told Reuters. The percentage of patients who had a glycated hemoglobin, or blood sugar, level of 6.5% or less was 73.5% in the CagriSema group and 15.9% in the placebo group. Dr. Davies acknowledged questions about why many patients in the trials were not given the highest tested dose. "Those patients on lower doses actually had higher weight loss reduction," she said. "We've not really seen that before because we have not had powerful treatments that have got people close to target." CagriSema is a weekly injection that combines Novo's blockbuster GLP-1 drug Wegovy with another molecule, cagrilintide, that mimics a hunger-suppressing pancreatic hormone called amylin. The CagriSema Phase 3 trial results "compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class," Dr. Davies said. Eli Lilly's tirzepatide, sold under the brand name Zepbound for weight loss, works by stimulating GLP-1 along with a second gut hormone called GIP. It was shown to help obese and overweight adults lose 22% of their weight over 72 weeks. Dr. Davies said it makes sense to have more options for patients, including "theoretical benefits" with amylin, which has been shown in animal studies to boost energy expenditure. If that effect is seen in humans, it could help mitigate the body's metabolic adaptation to weight loss, she said. Novo Nordisk said it plans to file for regulatory approvals for CagriSema in the first quarter of 2026. "We expect to see approval maybe around the beginning of 2027," Martin Holst Lange, head of development at Novo Nordisk, told Reuters. The company is conducting several other trials of CagriSema, including measuring its impact on cardiovascular outcomes. Lange said trial patients given lower doses of the drug often lost as much weight as those given higher doses, suggesting the need for flexibility including longer time periods between dose escalation. "This also allows them to lose their body weight at a pace that isn't too steep. It also mitigates side effects," he said. (Reporting By Deena Beasley, Editing by Franklin Paul)
Yahoo
an hour ago
- Yahoo
If You Can Only Buy 1 Cathie Wood Stock in 2025, It Should Be This
Cathie Wood, founder, CEO and chief investment officer of Ark Invest, continues to make headlines for her high-conviction approach to disruptive innovation. Her flagship fund, the Ark Innovation ETF (ARKK), has posted a 52.9% return in the past 52 weeks, reflecting investor confidence. Known for identifying transformational themes early, Wood maintains focused exposure to industries like genomics, autonomous technology, and blockchain. Within this context, Natera (NTRA) has drawn sharp relevance. The company leads in cell-free DNA testing and precision medicine, aligning directly with Ark's long-term thesis. CoreWeave Just Revealed the Largest-Ever Nvidia Blackwell GPU Cluster. Should You Buy CRWV Stock? AMD Is Gunning for Nvidia's AI Chip Throne. Should You Buy AMD Stock Now? The Saturday Spread: Statistical Signals Flash Green for CMG, TMUS and VALE Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For investors seeking a stock that fits the Ark playbook, Natera may represent one of the most fundamentally aligned additions under Wood's current investment lens. Based in Austin, Texas, stands Natera (NTRA), a pioneer in the field of cell-free DNA and genetic testing. The $23.3 billion biotech firm's arsenal includes powerful offerings like Panorama for prenatal screening, Signatera for real-time cancer surveillance, and Prospera, which sharpens the lens on transplant rejection. Over the last three months, the stock has climbed 16.9%, leaving the broader S&P 500 Index's ($SPX) 5.4% gain behind. On May 8, Natera opened the books on its first-quarter, and the results exceeded Wall Street expectations. Investors responded swiftly, with the stock inching up 1.5% the same day. Natera posted $501.8 million in total revenues, a 36.5% year-over-year increase that soared past Wall Street's $443.3 million forecast. Behind those numbers were powerhouse operations. The company processed 855,100 tests during the quarter, up 16.2% year over year. Women's health volumes climbed meaningfully over the fourth quarter, but it was Signatera that stole the spotlight. The personalized, tumor-informed molecular residual disease test reached new heights, recording its highest volume quarter ever. Clinical volumes for Signatera grew 52% year over year, with a sequential gain of roughly 16,005 units over Q4, marking the most significant quarter-on-quarter growth to date. Gross margins landed at 63.1%, reflecting solid cost discipline. Moreover, Natera's net loss narrowed 1% from the year-ago period to $66.9 million. Also, the company managed to trim its loss per share by 10.7% to $0.50, outperforming analysts' projections of a $0.59 loss per share. As for liquidity, the balance sheet remained in good shape. Cash, cash equivalents and restricted cash climbed to $973.8 million, up from $945.6 million on Dec 31, 2024. CEO Steve Chapman has made no secret of the firm's long-term vision. He believes Signatera could ultimately generate over $5 billion in annual revenue, and he emphasized that they are still playing in the shallow end of a much deeper market pool. In a move that reinforced this optimism, Natera has raised its full-year revenue guidance to between $1.94 billion and $2.02 billion. That is a $70 million boost from the midpoint of its earlier outlook, pointing to a 26% year-over-year growth. On the other hand, analysts expect the Q2 2025 loss per share to widen 100% year over year to $0.60. For FY25, the loss per share is projected to increase 37% to $2.10, but FY26 could bring relief, with a forecast 64.8% narrowing to $0.74, hinting that profitability may finally be within reach. Analysts seem to be singing in harmony when it comes to NTRA, marking it with a firm 'Strong Buy' rating. Out of 19 analysts following the stock, 16 have given it an enthusiastic 'Strong Buy' rating, and the remaining three have placed their bets on a 'Moderate Buy.' The average price target of $200.42 represents potential upside of 17.6%. Meanwhile, the Street-High target of $251 hints at a 48% climb from current levels. Such projections do not come lightly and often reflect deep-rooted confidence in future earnings momentum and strategic execution. On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Company makes game-changing breakthrough that could solve common issue with plant-based food — here's what you need to know
Let's be honest: Plant-based protein doesn't always taste great. Even if you love the idea of eating less meat for your health and the planet, the weird aftertaste of some plant-based meats can be hard to ignore. But that might be about to change. According to FoodNavigator USA, the flavor company T. Hasegawa USA has developed a high-tech, natural flavor that tackles the unpleasant "off" notes of plant proteins such as pea and soy. The whole technology (and science) behind it is pretty impressive. When meat sizzles in a pan or bread gets crispy in the toaster, the Maillard reaction creates craveable aromas and flavors. But plant proteins such as soy and pea don't react the same way during cooking, which can leave them tasting bland or, worse, beany and bitter. If companies want people to go for meat alternatives, there's a need to focus on options that taste good and have pleasant textures. As Mark Webster, vice president of sales and marketing at T. Hasegawa, said, "That is where the headwind is." The T. Hasegawa team tackled this problem by developing a natural flavor technology called Plantreact that increases Maillard reactions — the chemical processes that give so-called browned foods their flavors. This innovation doesn't stop with fake meats. The same flavor solution can also recreate creamy, dairy-like notes in alternative milks and other nondairy products. That's huge for people who love the idea of oat or almond milk but miss the full-bodied taste of cow's milk. Plantreact has been in the works for a while, but it's now ready to hit the market. T. Hasegawa is already working with food brands to roll it out in products. Better flavor means plant-based foods are more enjoyable, which makes it easier for more people to cut back on animal products and reduce pollution, conserve water, and shrink their carbon footprints. This tech is already being explored by plant-based brands looking to improve their products, and it may soon appear in alternative meat and dairy products at your local grocery store. Combined with the work of companies such as Meati and Perfect Day, this kind of innovation helps build a future in which eating more sustainably doesn't mean compromising on taste. Why do you eat plant-based foods? The health benefits It's cheaper It's good for the planet I prefer the taste Click your choice to see results and speak your mind. Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.
